Mads Krogs­gaard Thom­sen hands off CSO job at No­vo Nordisk af­ter a 30-year run, then piv­ots to CEO post at huge No­vo ...

5 years ago
People

Roche and Genen­tech's lat­est AI col­lab­o­ra­tor rais­es $25M Se­ries A to rein­vent one of the old­est can­cer tar­gets

5 years ago
Financing
AI

Bio­gen sweeps out a Parkin­son’s drug on PhII fail­ure as an­a­lysts raise alarms about pro­ject­ed rev­enue slide — ...

5 years ago
R&D

Bris­tol My­ers Squibb turns in pri­or­i­ty re­view vouch­er for sup­ple­men­tal in­di­ca­tion on an old Cel­gene drug

5 years ago
FDA+

Covid-19 roundup: EU re­stric­tions al­ready hav­ing im­pact, Japan says; Mod­er­na seeks to up vial ca­pac­i­ty, sees ...

5 years ago
Coronavirus

Jazz vaults in­to the cannabi­noid field with $7.2B GW Phar­ma buy­out

5 years ago
Deals

EU mis­tak­en­ly leaves key parts of As­traZeneca Covid-19 con­tract unredact­ed, re­veal­ing costs and So­ri­ot's ...

5 years ago
Coronavirus

Biotech scan­dal drags on as the feds on­ly score par­tial vic­to­ry against ex­ecs charged with cook­ing the books

5 years ago
People

Ea­ger to re­deem its Covid-19 vac­cine, As­traZeneca touts 82.4% ef­fi­ca­cy for 12-week dos­ing sched­ule — but will the ...

5 years ago
R&D
Coronavirus

Af­ter rais­ing $465M, Kurt von Em­ster talks about mon­ey, bio­phar­ma and a new breed of in­vestor: 'The ris­ing tide is ...

5 years ago
Deals

Glax­o­SmithK­line dou­bles down on Cure­Vac's mR­NA tech, bets $180M on the hunt for next-gen vac­cine

5 years ago
Deals
Coronavirus

Am­gen scraps or halts a slate of 5 can­cer stud­ies in a se­ries of set­backs. But ex­ecs fo­cus on mas­ter­ing 'in­duced ...

5 years ago
R&D

Neu­ro­crine ax­es Parkin­son's col­lab with Voy­ager af­ter safe­ty is­sues, jeop­ar­diz­ing biotech's long-run­ning cen­ter­piece

5 years ago
Pharma

James Sabry adds an­oth­er weapon to Roche-Genen­tech ar­se­nal; Dai­ichi Sankyo adds ADC #6

5 years ago
News Briefing

Mar­tin Shkre­li’s old com­pa­ny touts PhI­II win, guns for ac­cel­er­at­ed ap­proval

5 years ago
R&D

WuXi STA snaps up Bris­tol My­ers Squibb fa­cil­i­ty, plants feet in Eu­ro­pean CD­MO mar­ket­place

5 years ago
Deals
Manufacturing

FDA lifts clin­i­cal hold on Mus­tang Bio's lentivi­ral gene ther­a­py, paving the way for quick jump in­to piv­otal tri­al

5 years ago
Cell/Gene Tx
FDA+

Durec­t's non-opi­oid painkiller brush­es aside check­ered past, gain­ing FDA ap­proval in shoul­der surg­eries

5 years ago
FDA+

Two years af­ter flop, Verona gets a win as it preps for piv­otal Phase III tri­als

5 years ago
R&D

Pfiz­er pre­dicts a $15B avalanche of cash from its Covid-19 vac­cine in 2021 as the R&D team claims a big spike in the ...

5 years ago
Coronavirus

Eli Lil­ly's new can­cer R&D chief has some things to say about drug dis­cov­ery, the dif­fi­cul­ty in find­ing new drugs to ...

5 years ago
People
R&D

Im­muno­vant vol­un­tar­i­ly halts stud­ies on sole drug af­ter sur­prise cho­les­terol find­ings, FcRn ri­val ar­genx surges

5 years ago
R&D

Ver­tex is poised for a shop­ping spree. But it’s still un­clear just what might go in­to their bas­ket — and at least ...

5 years ago
Deals

Covid-19 roundup: In­ter­im analy­sis sug­gests Russ­ian vac­cine is 91.6% ef­fec­tive; US inks big deal with Aus­tralian ...

5 years ago
Coronavirus
First page Previous page 748749750751752753754 Next page Last page
A service from the Financial Times